Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12027407 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL22209113 | 0.84 | GAA (0.45) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL71840 | 0.84 | GAA (0.45) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL2757584 | 0.84 | GAA (0.45) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL20486 | 0.84 | GAA (0.45) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL16572524 | 0.83 | CA12 (0.45) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL241884 | 0.83 | CA1 (0.52) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL3315459 | 0.83 | GAA (0.52) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL19677579 | 0.82 | ALDH1A1 (0.53) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL57036 | 0.81 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105347-A1 | COMPOSITION, METHOD FOR PRODUCING FLUTICASONE FURANCARBOXYLIC ACID ESTER, METHOD FOR PURIFYING FLUTICASONE FURANCARBOXYLIC ACID ESTER, AND METHOD FOR PRODUCING LABELED COMPOUND | アルプス薬品工業株式会社 | 2025-05-22 | — | — | WO | claimed |
| CN-110504017-B | Preparation and application method of tracer | 哈尔滨医科大学 | 2022-06-10 | — | — | CN | claimed |
| CN-112752740-A | Process for the preparation of fluoromethyl-18 labelled radiopharmaceutical agents using selective azide substitution and precursor scavenging | BIK治疗公司 | 2021-05-04 | — | — | CN | claimed |
| CN-112479940-A | Production process of high-purity fluoromethyl p-toluenesulfonate | 衢州氟瑞医药科技有限公司 | 2021-03-12 | — | — | CN | claimed |
| US-20210015439-A1 | MOLECULAR IMAGING METHOD FOR EVALUATING LIVER REGENERATION CAPACLITY AFTER ALPPS OPERATION | UNIV HARBIN MEDICAL (CN) | 2021-01-21 | — | — | US | claimed |
| WO-2020059986-A1 | METHOD FOR PREPARING FLUORINE-18-LABELED FLUOROMETHYL-SUBSTITUTED RADIOPHARMACEUTICALS USING SELECTIVE AZIDE SUBSTITUTION REACTION AND PRECURSOR SCAVENGING | 주식회사 바이오이미징코리아 | 2020-03-26 | — | — | WO | claimed |
| US-20260125389-A1 | MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| US-12606570-B2 | Deuterated compounds and imaging agents for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-22 | — | — | US | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | UNIV ANTWERPEN (BE) | 2025-11-06 | — | — | US | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1741703-A1 | PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
| EP-1311192-A4 | $G(IN VIVO) IMAGING | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20040131544-A1 | Positron emission tomography ; multistage process; medical diagnosis | MACLEAN DEREK (US) | 2004-07-08 | — | — | US | disclosed |
| EP-1311192-A1 | $G(IN VIVO) IMAGING | Glaxo Group Limited (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002102250-A1 | $G(IN VIVO) IMAGING | GLAXO GROUP LIMITED (GB) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606570-B2 | Deuterated compounds and imaging agents for imaging huntingtin protein | HTT, HYPK, ATXN2 | ALDH1A1 4171/4885CYP3A4 4867/4885CYP2C9 4468/4885 |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | ALDH1A1 2038/4885CYP3A4 4012/4885CYP2C9 3655/4885 |
| US-20260125389-A1 | MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF | PKMYT1, PKN1, ROS1 | ALDH1A1 4554/4885CYP3A4 4205/4885CYP2C9 3494/4885 |
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FIBP, FGF1, FGFR1 | ALDH1A1 1162/4885CYP3A4 3313/4885CYP2C9 3051/4885 |
| US-20040131544-A1 | Positron emission tomography ; multistage process; medical diagnosis | FAP, FIP1L1, PIK3CA | ALDH1A1 1612/4885CYP3A4 372/4885CYP2C9 949/4885 |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, WEE1 | ALDH1A1 3317/4885CYP3A4 3135/4885CYP2C9 2427/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | ALDH1A1 326/4885CYP3A4 157/4885CYP2C9 116/4885 |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | CHEK1, CHEK2, PDCD1 | ALDH1A1 3803/4885CYP3A4 4836/4885CYP2C9 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.